Accelerant vs Hagerty
ARX and HGTY side by side, both in insurance agents, brokers, and service. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ARX and HGTY compare
Hagerty is the larger company, worth 1.3 times as much as Accelerant ($5.6B against $4.3B).
Accelerant grew revenue faster over the last twelve months (54.6% versus 5.2% for Hagerty).
Hagerty scores higher on the StockData Score (2 against 1 for Accelerant), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ARX | HGTY |
|---|---|---|
| Size and price | ||
| Market cap | $4.3B | $5.6B |
| Share price | $19.86 | $16.25 |
| Change, 1 year | 46.5% | 18.7% |
| Change, 5 years | 28.5% | 62.8% |
| Beta (5Y) | 0.34 | 0.01 |
| Employees | – | 1,891 |
| StockData Score | ||
| Total score | 1 | 2 (better) |
| Valuation score | 0 | 0 |
| Growth score | 1 | 1 |
| Performance score | 0 | 0 |
| Health score | 0 | 1 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 3.8× (better) | 3.9× |
| P/B | 6.0× (better) | 25.9× |
| EV/EBITDA | – | 81.4× |
| P/FCF | – | 20.1× |
| FCF yield | – | 5.0% |
| Growth | ||
| Revenue growth (TTM) | 54.6% (better) | 5.2% |
| Revenue growth, 5Y average | – | 23.9% |
| EPS growth (TTM) | −3267% | – |
| Profitability | ||
| FCF margin | – | 19.4% |
| Financial health | ||
| Debt / equity | – | 1.00 |
| Net debt / EBITDA | – | −1.13 |
| Altman Z-score | 0.21 | 2.77 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 29.7% | 27.3% |
| Held by insiders | 73.7% | 85.9% |
| Insider net buying, 12 months | −$21.6M (better) | −$457M |
| Superinvestors holding | 1 | 2 (better) |
| Short interest, % of float | 5.2% | 2.9% |
Go deeper
- ARX stock overview
- ARX income statement
- ARX valuation and score
- HGTY stock overview
- HGTY income statement
- HGTY valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.